Literature DB >> 16456234

G protein-linked cell signaling and cardiovascular functions in diabetes/hyperglycemia.

Shehla Hashim1, Yuan Li, Madhu B Anand-Srivastava.   

Abstract

Vascular complications, including impaired contractility and increased cell proliferation, are the most common complications with diabetes. Chronic hyperglycemia seems to be an important contributing factor in this process. Various signaling pathways are implicated in diabetes/hyperglycemia-induced impaired vascular functions. Nonenzymatic glycation, enhanced production of diacylglycerol, increased activity of membranous protein kinase C (PKC), and increased oxidative stress have been proposed to explain the adverse effects of hyperglycemia on vascular smooth muscle cells. Hyperglycemia-induced stimulation of L-type Ca2+ channel via G protein-coupled adenylyl cyclase/cAMP and phospholipase C/PKC pathways also has been shown. In addition, hyperglycemia has been reported to decrease the availability of nitric oxide in humans, which may contribute to all the hemodynamic and physiological changes occurring in diabetes. G protein-adenylyl cyclase signaling that plays an important role in the regulation of cardiovascular functions also has been reported to be impaired in diabetes and under hyperglycemic conditions. In this review article, various G protein-linked cell signaling and functions in diabetes and hyperglycemia are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456234     DOI: 10.1385/CBB:44:1:051

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

1.  Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury.

Authors:  Neeta Adhikari; David L Basi; Marjorie Carlson; Ami Mariash; Zhigang Hong; Ute Lehman; Sureni Mullegama; Edward K Weir; Jennifer L Hall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-14       Impact factor: 8.311

2.  Synergistic activation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase by Src kinase elevates superoxide in type 2 diabetic, Zucker fa/fa, rat liver.

Authors:  Rakhee S Gupte; Beverly C Floyd; Mark Kozicky; Shimran George; Zoltan I Ungvari; Vanessa Neito; Michael S Wolin; Sachin A Gupte
Journal:  Free Radic Biol Med       Date:  2009-02-20       Impact factor: 7.376

3.  Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells.

Authors:  Manuel F Navedo; Yukari Takeda; Madeline Nieves-Cintrón; Jeffery D Molkentin; Luis F Santana
Journal:  Am J Physiol Cell Physiol       Date:  2009-10-21       Impact factor: 4.249

4.  Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH.

Authors:  Sabrina Serpillon; Beverly C Floyd; Rakhee S Gupte; Shimran George; Mark Kozicky; Venessa Neito; Fabio Recchia; William Stanley; Michael S Wolin; Sachin A Gupte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

5.  Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy.

Authors:  Li Qin Tang; Feng Ling Wang; Ling Na Zhu; Fei Lv; Sheng Liu; Shan Tang Zhang
Journal:  Mol Biol Rep       Date:  2012-12-25       Impact factor: 2.316

6.  Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.

Authors:  Feng Ling Wang; Li Qin Tang; Feng Yang; Ling Na Zhu; Ming Cai; Wei Wei
Journal:  Mol Biol Rep       Date:  2012-11-30       Impact factor: 2.316

7.  Neurotensin modulates the migratory and inflammatory response of macrophages under hyperglycemic conditions.

Authors:  Liane I F Moura; Lucília Silva; Ermelindo C Leal; Ana Tellechea; Maria Teresa Cruz; Eugénia Carvalho
Journal:  Biomed Res Int       Date:  2013-08-13       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.